Abstract
Individuals with lymphoid malignancies have an increased mortality risk from COVID-19. Paradoxically, this population is least likely to be protected by SARS-CoV-2 vaccination as a result of disease- or treatment-related immunosuppression. Current data on vaccine responses in persons with lymphoid malignancies is limited.
PROSECO is a UK multi-centre prospective observational study evaluating COVID-19 vaccine immune responses in individuals with lymphoma. This early interim analysis details the antibody responses to first- and second-SARS-CoV-2 vaccination with either BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca), in 129 participants. Responses are compared to those obtained in healthy volunteers.
The key findings of this interim analysis are first, 61% of participants who are vaccinated during or within 6 months of receiving systemic anti-lymphoma treatment, do not have detectable antibodies despite two doses of vaccine. Second, individuals with curable disease such has Hodgkin (6/6) and aggressive B-cell non-Hodgkin lymphoma (13/16) develop robust antibody levels to either first or second doses, when vaccinated > 6 months after treatment completion. Third, participants incurable, indolent lymphomas have reduced antibody levels to first and second vaccine doses, irrespective of treatment history. Finally, whilst there was no difference in antibody responses between BNT162b2 and ChAdOx1 in lymphoma participants, BNT162b2 induces 11-fold higher antibody responses than ChAdOx1 after the second dose in healthy donors.
These findings serve to reassure the community that individuals with treated Hodgkin and aggressive B-NHL can develop antibody responses to SARS-CoV-2 vaccine. Simultaneously it also highlights the critical need to identify an alternative strategy against COVID-19 for those undergoing systemic anti-lymphoma treatment, and for individuals with indolent lymphomas.
Competing Interest Statement
SHL, NC, MJ, DJP, AO, PWMJ and DG declare no competing interests. CF receives consultancy fees from AstraZeneca and participates in an advisory board for AstraZeneca, MA receives research funding from Pfizer, GPC receives research funding from Pfizer and participates in advisory boards for AstraZeneca and Pfizer, and AJD reports receiving research funding and honoraria from AstraZeneca and Janssen.
Clinical Trial
NCT04858568
Funding Statement
The PROSECO study is funded by The Vaccine Blood Cancer Research Funding Consortium, and all charity partners including Blood Cancer UK (21009), and supported by Cancer Research UK Advanced Clinician Scientist Fellowship to SHL (A27179), Cancer Research UK/NIHR Southampton Experimental Cancer Medicine Centre funding and the NIHR Clinical Research Facility Southampton Research Biorepository (SRB). DG receives support from the NIHR Great Ormond Street Biomedical Research Centre. No pharmaceutical company contributed to this study or the writing of this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work is approved by local research ethics committees and the UK NHS Health Research Authority (IRAS 294739; 233768). Healthy controls were vaccinees who received vaccine as part of the government rollout and donated serum post vaccination for essay evaluation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data from this study is available after study completion on request to the corresponding author.
